|Mr. Richard F. Pops||Chairman and Chief Exec. Officer||2.57M||6.43M||55|
|Mr. Shane Martin Cooke||Pres||1.31M||N/A||55|
|Dr. Floyd E. Bloom M.D.||Co-Founder and Director||85.5k||N/A||80|
|Mr. James M. Frates||Chief Financial Officer, Sr. VP and Treasurer||876.25k||2.57M||50|
|Ms. Kathryn L. Biberstein||Chief Admin. Officer, Chief Compliance Officer, Chief Risk Officer, EVP and Sec.||1.08M||1.66M||58|
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The companys marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes plc’s ISS Governance QualityScore as of July 1, 2017 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 6; Compensation: 2.